Novo Nordisk to file Lantus rival Degludec in US after EU
This article was originally published in Scrip
Executive Summary
Novo Nordisk has filed in the EU its ultra-long acting basal insulin analogue Degludec (insulin degludec) and its insulin combination analogue Degludec Plus (70% Degludec, 30% Novo Nordisk's NovoLog (insulin aspart). The company expects to file approval documentation on its potential rivals to Sanofi-Aventis' Lantus (insulin glargine) in the US within two weeks.